Press releases
Press releases dating back to 2009 are available below. Search them by keyword or browse by year/business category. Press releases for our local operating companies can be viewed on our market websites.
-
GSK Cervarix® two-dose schedule receives European marketing authorisation
GSK announced today that the European Commission has granted marketing authorisation for its cervical cancer vaccine Cervarix.
Read more -
GSK and MMV announce FDA Breakthrough Therapy designation for tafenoquine for Plasmodium vivax malaria
GSK and Medicines for Malaria Venture (MMV) announced today that the FDA has granted Breakthrough Therapy designation for tafenoquine.
Read more -
Update on Patent Ruling on ViiV Healthcare's EPZICOM® and TRIZIVIR®
Update on Patent Ruling on ViiV Healthcare's EPZICOM® and TRIZIVIR®
Read more -
GSK announces 1 million innovation prize for bioelectronics research
GSK is announcing today a $1 million dollar prize for innovation in the emerging area of bioelectronics research.
Read more -
ANORO™ ELLIPTA™ approved as first once-daily dual bronchodilator for the treatment of COPD in the US
GlaxoSmithKline plc and Theravance, Inc. today announced that the US Food and Drug Administration (FDA) has approved ANORO ELLIPTA.
Read more -
GSK announces changes to its global sales and marketing practices to further ensure patient interests come first
GSK today set out plans to evolve the way it sells and markets its products to healthcare professionals.
Read more -
GSK and Genmab Receive Priority Review from FDA for Arzerra® (ofatumumab) as 1st Line Treatment for Chronic Lymphocytic Leukaemia (CLL)
GSK and Genmab Receive Priority Review from FDA for Arzerra® (ofatumumab) as 1st Line Treatment for Chronic Lymphocytic Leukaemia (CLL)
Read more -
GSK initiates voluntary open offer to increase stake in its pharmaceuticals subsidiary in India
GSK today announced a Voluntary Open Offer to increase its stake in its publicly-listed pharmaceuticals subsidiary in India.
Read more -
GSK announces £200 million investment in UK advanced manufacturing and science
GSK today announced a series of investments totalling approximately £200 million which will support the delivery of the company's pipeline of new medicines and create a centre f...
Read more -
Update regarding 2010 Nature Medicine study
A GSK research paper published in 2010 that was found earlier this year to contain incorrect data has now been retracted by Nature Medicine.
Read more -
GSK and Theravance announce positive results from pivotal phase III study for fluticasone furoate/vilanterol in asthma
GSK and Theravance, Inc. today announced positive results from a phase III efficacy and safety study of fluticasone furoate “FF”/vilanterol “VI”.
Read more -
Synflorix™ receives European marketing authorisation for additional pneumonia indication
GSK today announced that the European Commission (EC) has granted marketing authorisation for an additional indication for Synflorix™
Read more -
GSK launches global consortium with six renowned cancer research centres
GSK announced today the formation of the Oncology Clinical and Translational Consortium (OCTC)
Read more -
Regulatory Update - GSK receives positive CHMP opinion for Cervarix™ two-dose schedule
GSK announces that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) is recommending marketing authorisation for a two-dose schedule in 9-14 ...
Read more -
H5N1 vaccine approved by the U.S. FDA as pandemic influenza preparedness measure
GSK announced today that the U.S. Food and Drug Administration (FDA) has approved its pandemic Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (also referred to as Q-Pa...
Read more -
GSK Responds to FDA Decision on Avandia (rosiglitazone)
GSK announced today that the U.S. Food and Drug Administration (FDA) has eased restrictions on patient access to Avandia (rosiglitazone), following an FDA Advisory Committee rev...
Read more -
Tivicay® (dolutegravir) receives positive CHMP opinion in Europe for the treatment of HIV
ViiV Healthcare today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending ...
Read more -
GSK and Amicus Therapeutics announce revised Fabry agreement
GSK and Amicus Therapeutics today announced that Amicus has obtained global rights to develop and commercialise the investigational pharmacological chaperone migalastat HCl as a...
Read more -
RELVAR® ELLIPTA® receives European marketing authorisation for the treatment of asthma and COPD
GSK and Theravance, Inc. announced today that the European Commission has granted marketing authorisation for RELVAR® ELLIPTA®.
Read more -
Five inspirational organisations from Malawi, Bangladesh, Mali, Kenya, and Colombia recognised by GSK and Save the Children
A simple low-cost device that helps newborn babies to breathe and has the potential to transform the life chances for thousands of African babies has been awarded the highest fu...
Read more
Find out more about us
-
About us
We are a science-led global healthcare company with a special purpose to improve the quality of human life.
-
Products
We research and develop a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare
-
Research and development
Science can improve health and well-being in so many ways, from the development of everyday healthcare products to medicines and vaccines.
-
Behind the science
Explore innovations in medicines, vaccines & consumer healthcare from inside and outside our labs. Go #BehindTheScience to see for yourself
